Advances in Tumor Microenvironment and Underlying Molecular Mechanisms of Bladder Cancer: a Systematic Review

Overview

Journal Discov Oncol

Publisher Springer

Specialty Oncology

Date 2024 Apr 11

PMID 38602556

Authors

Liu Tang

Haifei Xu

Tong Wu

Wenhao Wu

Yuhao Lu

Jijia Gu

Xiaoling Wang

Mei Zhou

Qiuyang Chen

Xuan Sun

Hongzhou Cai

Affiliations

Soon will be listed here.

Abstract

Bladder cancer is one of the most frequent malignant tumors of the urinary system. The prevalence of bladder cancer among men and women is roughly 5:2, and both its incidence and death have been rising steadily over the past few years. At the moment, metastasis and recurrence of advanced bladder cancer-which are believed to be connected to the malfunction of multigene and multilevel cell signaling network-remain the leading causes of bladder cancer-related death. The therapeutic treatment of bladder cancer will be greatly aided by the elucidation of these mechanisms. New concepts for the treatment of bladder cancer have been made possible by the advancement of research technologies and a number of new treatment options, including immunotherapy and targeted therapy. In this paper, we will extensively review the development of the tumor microenvironment and the possible molecular mechanisms of bladder cancer.

Citing Articles

A new perspective on macrophage-targeted drug research: the potential of in bladder cancer immunotherapy.

Zhao Z, Jia H, Sun Z, Li Y, Liu L Front Immunol. 2024; 15:1485109.

PMID: 39691708 PMC: 11649672. DOI: 10.3389/fimmu.2024.1485109.

References

Gunes M, Gecit I, Pirincci N, Kemik A, Purisa S, Ceylan K . Plasma human neutrophil proteins-1, -2, and -3 levels in patients with bladder cancer. J Cancer Res Clin Oncol. 2012; 139(2):195-9. DOI: 10.1007/s00432-012-1305-0. View

Eruslanov E, Neuberger M, Daurkin I, Perrin G, Algood C, Dahm P . Circulating and tumor-infiltrating myeloid cell subsets in patients with bladder cancer. Int J Cancer. 2011; 130(5):1109-19. DOI: 10.1002/ijc.26123. View

Yuan Y, Wang F, Liu X, Gong D, Cheng H, Huang S . Angiogenin is involved in lung adenocarcinoma cell proliferation and angiogenesis. Lung Cancer. 2009; 66(1):28-36. DOI: 10.1016/j.lungcan.2008.12.027. View

Chang C, Wang H, Liu J, Pan C, Zhang D, Li X . Infection Promoted the Proliferation of Oral Squamous Cell Carcinoma Cells through the miR-21/PDCD4/AP-1 Negative Signaling Pathway. ACS Infect Dis. 2019; 5(8):1336-1347. DOI: 10.1021/acsinfecdis.9b00032. View

Okita K, Hatakeyama S, Momota M, Soma O, Hamano I, Tanaka T . Frailty is significantly associated with the type of urinary diversion in patients with muscle-invasive bladder cancer. Int J Urol. 2020; 27(8):649-654. DOI: 10.1111/iju.14263. View

Bendre M, Montague D, Peery T, Akel N, Gaddy D, Suva L . Interleukin-8 stimulation of osteoclastogenesis and bone resorption is a mechanism for the increased osteolysis of metastatic bone disease. Bone. 2003; 33(1):28-37. DOI: 10.1016/s8756-3282(03)00086-3. View

Sun Y, Sedgwick A, Khan M, Palarasah Y, Mangiola S, Barrow A . A Transcriptional Signature of IL-2 Expanded Natural Killer Cells Predicts More Favorable Prognosis in Bladder Cancer. Front Immunol. 2021; 12:724107. PMC: 8631443. DOI: 10.3389/fimmu.2021.724107. View

Dang E, Barbi J, Yang H, Jinasena D, Yu H, Zheng Y . Control of T(H)17/T(reg) balance by hypoxia-inducible factor 1. Cell. 2011; 146(5):772-84. PMC: 3387678. DOI: 10.1016/j.cell.2011.07.033. View

Goossens S, Vandamme N, Van Vlierberghe P, Berx G . EMT transcription factors in cancer development re-evaluated: Beyond EMT and MET. Biochim Biophys Acta Rev Cancer. 2017; 1868(2):584-591. DOI: 10.1016/j.bbcan.2017.06.006. View

10.

Bulfone-Paus S, Bahri R . Mast Cells as Regulators of T Cell Responses. Front Immunol. 2015; 6:394. PMC: 4528181. DOI: 10.3389/fimmu.2015.00394. View

11.

Tamada K, Shimozaki K, Chapoval A, Zhai Y, Su J, Chen S . LIGHT, a TNF-like molecule, costimulates T cell proliferation and is required for dendritic cell-mediated allogeneic T cell response. J Immunol. 2001; 164(8):4105-10. DOI: 10.4049/jimmunol.164.8.4105. View

12.

Albayrak S, Zengin K, Tanik S, Atar M, Unal S, Imamoglu M . Can the neutrophil-to-lymphocyte ratio be used to predict recurrence and progression of non-muscle-invasive bladder cancer?. Kaohsiung J Med Sci. 2016; 32(6):327-33. DOI: 10.1016/j.kjms.2016.05.001. View

13.

Inoue K, Slaton J, Kim S, Perrotte P, Eve B, Bar-Eli M . Interleukin 8 expression regulates tumorigenicity and metastasis in human bladder cancer. Cancer Res. 2000; 60(8):2290-9. View

14.

Rice T, Ishwaran H, Hofstetter W, Kelsen D, Apperson-Hansen C, Blackstone E . Recommendations for pathologic staging (pTNM) of cancer of the esophagus and esophagogastric junction for the 8th edition AJCC/UICC staging manuals. Dis Esophagus. 2016; 29(8):897-905. PMC: 5591444. DOI: 10.1111/dote.12533. View

15.

Butt A, Mills K . Immunosuppressive networks and checkpoints controlling antitumor immunity and their blockade in the development of cancer immunotherapeutics and vaccines. Oncogene. 2013; 33(38):4623-31. DOI: 10.1038/onc.2013.432. View

16.

Zirakzadeh A, Sherif A, Rosenblatt R, Bergman E, Winerdal M, Yang D . Tumour-associated B cells in urothelial urinary bladder cancer. Scand J Immunol. 2019; 91(2):e12830. DOI: 10.1111/sji.12830. View

17.

Chau C, Steeg P, Figg W . Antibody-drug conjugates for cancer. Lancet. 2019; 394(10200):793-804. DOI: 10.1016/S0140-6736(19)31774-X. View

18.

Wang Y, Zhou S, Yang F, Qi X, Wang X, Guan X . Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis. JAMA Oncol. 2019; 5(7):1008-1019. PMC: 6487913. DOI: 10.1001/jamaoncol.2019.0393. View

19.

Hatogai K, Sweis R . The Tumor Microenvironment of Bladder Cancer. Adv Exp Med Biol. 2021; 1296:275-290. PMC: 8345230. DOI: 10.1007/978-3-030-59038-3_17. View

20.

Sarfaty M, Rosenberg J . Antibody-Drug Conjugates in Urothelial Carcinomas. Curr Oncol Rep. 2020; 22(2):13. DOI: 10.1007/s11912-020-0879-y. View